Corista and Visiopharm Integrate Capabilities to Offer Enhanced Digital Pathology Experience
CONCORD, Mass, Feb. 5, 2019 /PRNewswire-PRWeb/ -- Corista, an integrated pathology solutions leader, is excited to announce our integration with Visiopharm, a global provider of image analysis software. Corista will extend direct access to Visiopharm's Oncotopix® from within its award-winning DP3® comprehensive workflow suite.
Corista's DP3 is the digital pathology platform of choice for major medical organizations seeking to create a seamless pathology workflow that integrates with all major digital systems, including all whole slide scanners (WSI) and major laboratory information systems (LIS). The addition of Visiopharm's quantitative image analytics for analyzing data and images provides pathologists with powerful tools to improve their workflows.
The DP3 platform provides pathologists with embedded capabilities for reading cases, presenting tumor boards, collaborating with colleagues, supporting remote location consults, and facilitating a range of research and educational processes. With today's announcement, Corista and Visiopharm provide additional ease and powerful functionalities for pathologists while archiving the resulting charts and image insights directly within DP3. Physicians can access the Visiopharm algorithms directly from their DP3 Dashboard and no longer need to leave their desks to access a stand-alone terminal to conduct image analytic routines. Pathologists' access to Visiopharm's Oncotopix product suite from within DP3 extends the reach of valuable image analytics while reducing the time to perform each routine.
"Partnering with Visiopharm is an important extension of Corista's commitment to providing a complete laboratory workflow solution for analytics, streamlining the work environment for pathologists as they continue to deliver the most comprehensive, up to date, and timely patient care," Corista Founder, President and CEO Elizabeth Wingard said. "This addition to our platform will extend the use of analytics to a wider range of pathologists as they access these capabilities from inside the Corista platform, receiving results from each analysis directly into the case being reviewed."
"We are pleased to add Corista to our partner community, strengthening our support for the integration of solutions that create a more streamlined workflow for pathologists," said Amanda Lowe, Senior Vice President of Visiopharm. "Our joint customers will benefit from a digital pathology experience that will deliver improved efficiency and standardization."
The integration between the two platforms has been completed and is available for installation to existing customers.
About Corista
Corista delivers the industry's most extensive array of workflow, analytical and collaborative tools for pathology. Medical centers can seamlessly integrate with LIS/EHRs in a unified digital environment of whole-slide, gross and static pathology images. Physicians have 21st-century tools to collaborate, communicate, teach and report with access to 'best of breed' image analytics. Specialists can receive digital consults from remote physicians and patients from across the globe, and Investigator-initiated researchers have an R&D platform to apply their algorithms. Corista provides for a new level of interoperability for pathology, integrating WSI image scanning systems, image analytics and LIS/EHR platforms with a rich collaborative environment for physicians, patients, bio-tech and pharmaceutical scientists. This is Integrated Pathology(TM) only from Corista.
For more information, visit corista.com.
About Visiopharm
Visiopharm is a world leader in Augmented Pathology(TM) solutions. Leading biopharmaceutical companies, contract research organizations (CRO), academic medical centers, and hospital diagnostic pathology labs all over the world utilize our software platform for tissue-based research and diagnostics. Visiopharm provides scientists and pathologist with a scalable software solution that fits the needs and volumes of both research and diagnostic labs. Over the past 16 years, Visiopharm has grown into an international business with over 800 installations and countless more users. Visiopharm software is featured in over 1350 scientific publications since 2010 and is compatible with leading slide scanning systems and data management software. A growing network of authorized distributors and integration partners support the growth of Visiopharm solutions on several continents including North America, Europe, and Asia. Our headquarters is in the Medicon Valley of Denmark, with a branch office in the United Kingdom, and a North American office in Broomfield, Colorado.
Oncotopix® is a registered trademark of Visiopharm. Oncoptopix is CE-IVD in EU and For Research Use Only outside EU.
For more information, please visit Visiopharm.com.
SOURCE Corista
